Given PDAC’s broad resistance to mAb-based therapy [31], including immune checkpoint inhibitors [32], we used PDAC as a model disease to explore FcRn levels within circulating immune cells in tumor-bearing mice and cancer patients. The gene discussed is FCGRT; the disease is neoplasm.